Answers are grounded in this paper and cite their sources.
Highlights methodological innovations to optimize acute stroke clinical trials, suggesting advanced trial designs and imaging can improve future neuroprotection discovery.
With technological assistance, approaches to acute stroke trials may be improved. Dose selection, eligibility criteria, control of confounding factors and endpoints can each be optimised. Adaptive randomisation techniques and Bayesian approaches can assist not only dose selection, but also balance of prognostic factors between treatment groups. Magnetic resonance imaging can facilitate enrichment of the trial population with potential responders. Utilisation of existing trial databases can enhance statistical approaches to outcome assessment. Confounding imbalance may also be limited by controlling or adjusting for concomitant conditions and their management. Recent trials have not yet identified a neuroprotectant, but have greatly assisted the prospects of success.
No takes yet. Share an insight, caveat, or question.
Kennedy R. Lees (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: